{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:27:23Z","timestamp":1792427243566,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"DOI":"10.7759\/cureus.68786","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T13:12:02Z","timestamp":1725628322000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations"],"prefix":"10.7759","author":[{"given":"Nazeefa","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadi R","family":"Palvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibran A","family":"Azeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Thirunagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia Rauf  R","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247307","article-title":"Association of body mass index with health care expenditures in the United States by age and sex","volume":"16","author":"Ward ZJ","year":"2021","unstructured":"Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021, 16:e0247307. 10.1371\/journal.pone.0247307","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29262","article-title":"FDA-approved pharmacotherapy for weight loss over the last decade","volume":"14","author":"Idrees Z","year":"2022","unstructured":"Idrees Z, Cancarevic I, Huang L. FDA-approved pharmacotherapy for weight loss over the last decade. Cureus. 2022, 14:e29262. 10.7759\/cureus.29262","journal-title":"Cureus"},{"key":"ref3","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian CM","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016, 22:s176-85.","journal-title":"Am J Manag Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo X","year":"2022","unstructured":"Guo X, Zhou Z, Lyu X, et al.. The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis. Horm Metab Res. 2022, 54:458-71. 10.1055\/a-1844-1176","journal-title":"Horm Metab Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"18","author":"Liao C","year":"2023","unstructured":"Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2023, 18:e0289616. 10.1371\/journal.pone.0289616","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller TD","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022, 21:201-23. 10.1038\/s41573-021-00337-8","journal-title":"Nat Rev Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108549","article-title":"Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery?","volume":"21","author":"Kloock S","year":"2023","unstructured":"Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery?. Pharmacol Ther. 2023, 21:201-23. 10.1016\/j.pharmthera.2023.108549","journal-title":"Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari M","year":"2023","unstructured":"Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab Syndr Obes. 2023, 16:575-95. 10.2147\/DMSO.S387116","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"Br Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1172-8","article-title":"Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols","volume":"8","author":"Farrah K","year":"2019","unstructured":"Farrah K, Young K, Tunis MC, Zhao L. Risk of bias tools in systematic reviews of health interventions: an analysis of PROSPERO-registered protocols. Syst Rev. 2019, 8:280. 10.1186\/s13643-019-1172-8","journal-title":"Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4.","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey WT","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022, 28:2083-91. 10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki T","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al.. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022, 10:193-206. 10.1016\/S2213-8587(22)00008-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop FK","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:705-19. 10.1016\/S0140-6736(23)01185-6","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu Y","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, et al.. Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024, 12:184-95. 10.1016\/S2213-8587(23)00388-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial. J Am Med Assoc. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"J Am Med Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs Daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs Daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. J Am Med Assoc. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"J Am Med Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial. J Am Med Assoc. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"J Am Med Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn W","year":"2022","unstructured":"Ghusn W, De la Rosa A, Sacoto D, et al.. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022, 5:e2231982. 10.1001\/jamanetworkopen.2022.31982","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/282731-efficacy-of-different-doses-and-forms-of-the-glp-1-receptor-agonist-semaglutide-in-weight-reduction-among-non-diabetic-obese-or-overweight-populations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T13:12:04Z","timestamp":1725628324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/282731-efficacy-of-different-doses-and-forms-of-the-glp-1-receptor-agonist-semaglutide-in-weight-reduction-among-non-diabetic-obese-or-overweight-populations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.68786","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,6]]}}}